Literature DB >> 2939049

The effect of ciprofloxacin on methicillin-resistant Staphylococcus aureus.

S M Smith, R H Eng, E Berman.   

Abstract

Ciprofloxacin exhibited good in-vitro activity for methicillin-resistant Staphylococcus aureus with a MIC90 of 0.5 mg/l. The postantibiotic effect was 2.16 h. When ciprofloxacin was evaluated in combination studies with an aminoglycoside, none of the strains met the criterion of synergy as defined by FIC or FBC interaction indices of less than or equal to 0.25. However, killing kinetic experiments indicated that the combination of ciprofloxacin was synergistic for two of 12 strains with gentamicin and three of 12 strains with amikacin. Although the inoculum size had no effect on the rate of killing by ciprofloxacin, an increase in turbidity was noted when a high inoculum was tested. This increase in turbidity was due to the swelling of the staphylococci to several times their normal size and the formation of clusters of multicellular, incompletely divided staphylococci. If a high inoculum is used for susceptibility testing, this increase in turbidity could be misinterpreted as bacterial growth and could result in a false report of an elevated MIC.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2939049     DOI: 10.1093/jac/17.3.287

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

1.  Ciprofloxacin for methicillin-resistant Staphylococcus aureus infections.

Authors:  E A Piercy; D Barbaro; J P Luby; P A Mackowiak
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

2.  Ciprofloxacin therapy for methicillin-resistant Staphylococcus aureus infections or colonizations.

Authors:  S M Smith; R H Eng; F Tecson-Tumang
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

3.  Analysis of nosocomial outbreaks with multiply and methicillin-resistant Staphylococcus aureus (MRSA) in Germany: implications for hospital hygiene.

Authors:  W Witte; C Braulke; D Heuck; C Cuny
Journal:  Infection       Date:  1994       Impact factor: 3.553

4.  Monocyclic and tricyclic analogs of quinolones: mechanism of action.

Authors:  N H Georgopapadakou; B A Dix; P Angehrn; A Wick; G L Olson
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

5.  Ciprofloxacin resistance in methicillin- and gentamicin-resistant Staphylococcus aureus.

Authors:  P Maple; J Hamilton-Miller; W Brumfitt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-07       Impact factor: 3.267

Review 6.  Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use.

Authors:  J H Paton; D S Reeves
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

7.  Increasing resistance of Staphylococcus aureus to ciprofloxacin.

Authors:  T E Daum; D R Schaberg; M S Terpenning; W S Sottile; C A Kauffman
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

8.  Occurrence of quinolone resistance in Staphylococcus aureus from nosocomial infection.

Authors:  W Witte; H Grimm
Journal:  Epidemiol Infect       Date:  1992-12       Impact factor: 2.451

Review 9.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

10.  In vitro antistaphylococcal activity of pefloxacin alone and in combination with other antistaphylococcal drugs.

Authors:  R J Fass; V L Helsel
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.